The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial-Reference-Cited by-同舟云学术

The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial

Published:2011-12 Issue:1 Volume:12 Page:
ISSN:1465-993X
Container-title:Respiratory Research
language:en
Short-container-title:Respir Res

Author:

Taniguchi Hiroyuki, ,Kondoh Yasuhiro,Ebina Masahito,Azuma Arata,Ogura Takashi,Taguchi Yoshio,Suga Moritaka,Takahashi Hiroki,Nakata Koichiro,Sato Atsuhiko,Sugiyama Yukihiko,Kudoh Shoji,Nukiwa Toshihiro

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/1465-9921-12-93.pdf

Reference27 articles.

1. King TE, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, du Bois RM, INSPIRE Study Group: Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE.: A multicentre, randomized, placebo-controlled trial. Lancet. 2009, 374: 222-228. 10.1016/S0140-6736(09)60551-1.

2. du Bois RM: Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov. 2010, 9: 129-140. 10.1038/nrd2958.

3. Raghu G, Johnson WC, Lockhart D, Mageto Y: Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med. 1999, 159: 1061-1069.

4. Gahl WA, Brantly M, Troendle J, Avila NA, Padua A, Montalvo C, Cardona H, Calis KA, Gochuico B: Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab. 2002, 76: 234-242. 10.1016/S1096-7192(02)00044-6.

5. Nagai S, Hamada K, Shigematsu M, Taniyama M, Yamauchi S, Izumi T: Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med. 2002, 41: 1118-1123. 10.2169/internalmedicine.41.1118.

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real world experience on the effectiveness and safety of pirfenidone in patients with idiopathic pulmonary fibrosis in Taiwan;Frontiers in Medicine;2023-10-30

2. Body mass index and in-hospital mortality in patients with acute exacerbation of idiopathic pulmonary fibrosis;ERJ Open Research;2021-05-06

3. Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan;Respiratory Research;2020-11-30

4. Vital Capacity Measurement using Intensity Modulated Optical Fiber Sensor;Australian Journal of Electrical and Electronics Engineering;2020-07-02

5. Clinical staging of idiopathic pulmonary fibrosis;Respiratory Investigation;2020-03